Navigation Links
Zoledronic acid shows long-term benefit in survivorship for premenopausal ER-positive breast cancer
Date:12/7/2011

SAN ANTONIO Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.

Data from the Austrian Breast & Colorectal Cancer Study Group (ABCSG-12), reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011, confirmed and extended data reported at 48 months and 62 months of follow-up. Now at 84 months of follow-up, patients are experiencing drastically fewer recurrences of breast cancer and improved rates of survivorship without toxic side effects.

"We have confirmed what this trial showed initially, which was both exciting and surprising," said Michael Gnant, M.D., professor of surgery and president of the ABCSG at the Medical University of Vienna. "The continued success of this treatment means we can intervene early and still observe persistence of the benefit of treatment."

In the four-arm trial, researchers randomly assigned 1,803 premenopausal patients with early-stage, estrogen receptor (ER)-positive breast cancer to receive tamoxifen or anastrazole or each of these two treatments with zoledronic acid for three years. In the initial report, presented in 2008, Gnant and his colleagues reported significantly improved disease-free survival.

The most recent long-term data, at 84 months after treatment, revealed a 28 percent reduced risk for recurrence and a 36 percent reduction in risk for death among patients treated with zoledronic acid. Also, no patients experienced osteonecrosis of the jaw or renal failure thus, Gnant said, proving the safety of the treatment seven years later.

Researchers also found that patients aged older than 40 years with presumed complete ovarian blockade had a 34 percent reduced risk for recurrence and a 44 percent reduced risk for death. They found no significant survival benefits among patients aged younger than 40 years.

Gnant and his team said these data, considered with previously demonstrated bone-protective effects of zoledronic acid, suggest that adding zoledronic acid to adjuvant endocrine therapy including ovarian function suppression should be considered for premenopausal women with ER-positive early breast cancer.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women
2. Bone drug zoledronic acid may help prevent spread of early lung cancer
3. Novel approach to treating breast cancer shows great promise
4. Heads up Kobe Bryant! Research shows that trying for another 3-pointer is a mistake
5. Study shows many older Floridians have no backup plan after hanging up their keys
6. When babies awake: New study shows surprise regarding important hormone level
7. Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows
8. Study shows hospice caregivers need routine care interventions
9. Study shows medical marijuana laws reduce traffic deaths
10. Tools for predicting diabetes exist but are not used, research shows
11. LSUHSC research shows Rx with hyperbaric oxygen improved TBI and PTSD in vets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Leadership Series at Zuckerberg San Francisco General Hospital on April 5-7. The series ... behaviors and create new habits. The workshops cover a broad range of topics, ...
(Date:2/12/2016)... ... 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined ... Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System ... This will be the first Fisher House in Nevada, and will provide free ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Vail knee specialist ... Physician Leaders to Know in 2016 . The list consists of physicians establishing, leading ... to establish this list. , An Ambulatory Surgery Center, also known as an ...
(Date:2/12/2016)... San Ramon, CA (PRWEB) , ... February 12, 2016 , ... ... tissue donation in northern California and Nevada, announced a partnership with San Ramon Regional ... be transferred to the hospital’s facilities as a way to accommodate a more certain ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 ... Diagnostics in Personalized Medicine and Cancer Therapy. - ... High-Growth Diagnostic Testing Markets. - Key Diagnostic Testing ... - Molecular Diagnostics in Genetic Testing. - Molecular ... Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) ... ended December 31, 2015. The Company also filed its Quarterly ... year 2016 with the Securities and Exchange Commission today. ... 31, 2015 --> --> ... increased $2.6 million, or 95%, to $5.4 million from $2.8 ...
(Date:2/11/2016)... has committed to provide drug disposal kiosks in ... as part of a program to combat drug ... organization As You Sow. Conrad MacKerron , Senior ... to unneeded drugs because they lack easily accessible collection and ... Conrad MacKerron , Senior Vice President at As You ...
Breaking Medicine Technology: